Dual-Responsive Molecular Probe for Tumor Targeted Imaging and Photodynamic Therapy

Theranostics. 2017 Apr 10;7(7):1781-1794. doi: 10.7150/thno.18437. eCollection 2017.

Abstract

The precision oncology significantly relies on the development of multifunctional agents to integrate tumor targeting, imaging and therapeutics. In this study, a first small-molecule theranostic probe, RhoSSCy is constructed by conjugating 5'-carboxyrhodamines (Rho) and heptamethine cyanine IR765 (Cy) using a reducible disulfide linker and pH tunable amino-group to realize thiols/pH dual sensing. In vitro experiments verify that RhoSSCy is highly sensitive for quantitative analysis and imaging intracellular pH gradient and biothiols. Furthermore, RhoSSCy shows superb tumor targeted dual-modal imaging via near-infrared fluorescence (NIRF) and photoacoustic (PA). Importantly, RhoSSCy also induces strongly reactive oxygen species for tumor photodynamic therapy (PDT) with robust antitumor activity both in vitro and in vivo. Such versatile small-molecule theranostic probe may be promising for tumor targeted imaging and precision therapy.

Keywords: Dual-stimuli sensing; NIRF/PA imaging; Photodynamic therapy.; Small-molecule theranostic probe; tumor targeting.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / diagnostic imaging*
  • Adenocarcinoma / drug therapy*
  • Animals
  • Disease Models, Animal
  • Humans
  • MCF-7 Cells
  • Mice, Inbred BALB C
  • Molecular Probes / administration & dosage*
  • Molecular Probes / pharmacology*
  • Photochemotherapy / methods*
  • Photosensitizing Agents / administration & dosage*
  • Photosensitizing Agents / pharmacology*
  • Treatment Outcome

Substances

  • Molecular Probes
  • Photosensitizing Agents